References
- Gurney H., Dodwell D., Thatcher N., Tattersall M. Escalating drug delivery in cancer chemotherapy: A review of concepts and practice-part 2. Annals of Oncology 1993; 4: 103–115
- Pettengell R., Gurney H., Radford J.A., Deakin D., James R., Wilkinson P., Kane K., Bentley J., Crowfher D. Granulocyte colony-stimulating factor to prevent dose limiting neutropenia in non-Hodgkin's lymphoma: a randomised controlled trial. Blood 1992; 80: 1430–1436
- Duhrsen U., Villeval J.L., Boyd J., Kannourakis G., Morstyn G., Metcalf D. Effects of recombinant granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72: 2074–2081
- Lickliter J., Begley C.G., Boyd A., Grigg A.P. Combined chemotherapy and granulocyte colony-stimulating factor mobilise large numbers of peripheral blood progenitor cells in pretreated patients. Leukemia and Lymphoma 1994; 15: 91–97
- Pettengell R., Wall P.J., Thatcher N., Dexter M., Testa N.G. Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. Journal of Clinical Oncology 1995; 13: 148–156
- Ossenkoppele G.J., Schuurhuis G.J., Jonkhoff A.R., Drager A.M., Westra G., Oberink J.W., Legdeur M. C. J. C., De Kreuk A.M., Zweegman S., Huijgens P.C. G-CSF (filgrastim)-stimulated whole blood kept unprocessed at 4°C does support a BEAM-like regimen in bad risk lymphoma. Bone Marrow Transplantation 1996; 18: 427–431
- Grigg A.P., Wolf M., Levi J., Bartlett J., Green M. Escalated dose epirubicin-cyclophosphamide with filgrastim for patients with aggressive non-Hodgkin's lymphoma. Proc ASCO 1996; 15: 411, abstract no. 1255
- Goss G., Szer J., Grigg A.P. Intermediate dose cyclophosphamide combined with a growth factor is a safe and effective regimen for mobilisation of peripheral blood progenitor cells. Australian and New Zealand Journal of Medicine 1996; 26: 411–413
- Sheridan W., Begley C.G., To L.B., Grigg A.P., Szer J., Maher D., Green M.D., Rowlings P.A., McGrath K.M., Cebon J., Dyson P., Watson D., Bayly J., De Luca E., Tomila D., Hoffman E., Morstyn G., Juttner C.A., Fox R.M. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high dose chemotherapy for lymphoid malignancies. Bone Marrow Transplantation 1994; 14: 105–111
- Pettengell R., Woll P.J., O'Connor D.A., Dexter T.M., Testa N.G. Viability of haemopoietic progenitors from whole blood, bone marrow and leukapheresis product: effects of storage media, temperature and time. Bone Marrow Transplantation 1994; 14: 703–709
- Stiff P.J., Koester A.R., Weidner M.K., Dvorak K., Fisher R. Autologous bone marrow transplantation using unfractionated cells cryopreserved in dimethyl-sulfoxide and hydroxyethyl starch without controlled-rate freezing. Blood 1987; 70: 974–978
- Shipp M.A., Neuberg D., Janicek M., Canellos G.P., Shulman L.N. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose finding pilot study. Journal of Clinical Oncology 1995; 13(12)2916–2923
- Haas R., Mohle R., Fruhauf S., Goldschmidt H., Witt B., Flentje M., Wannenmacher M., Hunstein W. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3387–3794
- Pettengell R., Testa N.G., Swindell R., Crowther D., Dexter M. Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. Blood 1993; 82: 2239–2248
- Grigg A.P., Roberts A.W., Raunow H., Houghton S., Layton J., Boyd A.W., McGrath K.M., Maher D. Optimising dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995; 86: 4437–4445